Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
A Randomized Phase II Trial to Assess the Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients During Concurrent Chemotherapy
1 other identifier
interventional
60
1 country
1
Brief Summary
Malnutrition is very common in locally advanced nasopharyngeal carcinoma(NPC) patients undergoing current chemoradiotherapy (CRT) due to dysphagia, mucositis, nausea and other treatment-related problems. Malnutrition is associated with lower physical functioning, lower immune status, more severe (grade III/IV) late RT-induced toxicities, treatment interruption of chemo(radio)therapy, lower chemotherapy response rates, hospital readmission, impaired quality of life (QoL), and increased mortality. Although the international guidelines recommend early nutritional support in the presence of nutritional risk, the best type of nutritional intervention is still unclear. Individualized dietary counseling showed beneficial effects in nutritional intake, nutritional status and QoL in head and neck cancer patients undergoing RT or CRT-treatment; oral nutritional supplements (ONS) was most acceptable in Chinese NPC patients. Previous nutritional intervention trials in head-neck cancer patients have been conducted on small samples and did not clarify the role of oral nutritional supplements (ONS). Accordingly, although current guidelines recommend as grade A the use of ONS associated with dietary counseling for head-neck cancer patients undergoing RT, the efficacy of this nutritional intervention still needs to be evaluated in adequately sized and randomized clinical trials for Chinese NPC patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Jun 2014
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 3, 2016
CompletedFirst Posted
Study publicly available on registry
May 18, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedMarch 19, 2018
March 1, 2018
2.2 years
May 3, 2016
March 16, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Body weight(kg)change during concurrent chemotherapy
every week during the course of radiotherapy, up to 6-7 weeks
Secondary Outcomes (11)
Disease-free survival
2 years
Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment
every 2 weeks during the course of radiotherapy, up to 6-7 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v3.0
every week during the course of radiotherapy, up to 6-7 weeks
Body cell mass(kg) change measured by multifrequency segmental bioelectrical impedance analysis
every week during the course of radiotherapy, up to 6-7 weeks
Fat mass (kg) change measured by multifrequency segmental bioelectrical impedance analysis
every week during the course of radiotherapy, up to 6-7 weeks
- +6 more secondary outcomes
Study Arms (2)
ONS group
EXPERIMENTALIndividualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
control group
NO INTERVENTIONIndividualized dietary counseling during CRT
Interventions
ONS group will receive Healing Elements ONS everyday during CRT
Eligibility Criteria
You may qualify if:
- Newly diagnosed、pathologically proven nasopharyngeal carcinoma(Stage III/IV)
- Concurrent radiation and chemotherapy(platinum )
- Karnofsky score over 60
- No evidence of metastatic disease
- No significant cardiac, chest, gastrointestinal or renal morbidities
You may not qualify if:
- age \<18 years
- ongoing artificial nutrition
- refusal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai ninth people's hospital
Shanghai, Shanghai Municipality, 200011, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 3, 2016
First Posted
May 18, 2016
Study Start
June 1, 2014
Primary Completion
August 1, 2016
Study Completion
January 1, 2018
Last Updated
March 19, 2018
Record last verified: 2018-03